**Supplementary Table**

|  |
| --- |
| Clinical and pathological characteristics and LOH status of the sample. |
| Variables | Total(N=167) | LOH | *P* |
| Absence (n=115) | Presence (n=52) |
| Age, years | 55.95±11.96 | 56.24±11.42 | 55.29±13.170 | <0.586 |
| Tumour size, cm  | 2.93±2.24 | 2.69±1.83 | 3.48±2.910 | <0.220 |
| Tumour grade |  |  |  | <0.808 |
| I | 18 (10.8) | 13 (11.3) | 05 (9.6)0 |  |
| II | 83 (49.7) | 55 (47.8) | 28 (53.8) |  |
| III | 66 (39.5) | 47 (40.9) | 19 (36.5) |  |
| TNM stage |  |  |  | <0.053 |
| I-II | 109 (65.3)0 | 81 (70.4) | 028 (53.8) |  |
| III-IV | 58 (34.7) | 34 (29.6) | 024 (46.2) |  |
| Vascular invasion |  |  |  | <0.228 |
| No  | 77 (51.3) | 55 (55.0) | 22 (44.0) |  |
| Yes | 73 (48.7) | 45 (45.0) | 28 (56.0) |  |
| Molecular phenotype  |  |  |  | <0.988 |
| Luminal A | 51 (31.1) | 31 (27.4) | 20 (39.2) |  |
| Luminal B | 73 (44.5) | 57 (50.4) | 16 (31.4) |  |
| HER2 | 10 (6.1)0 | 06 (5.3)0 | 04 (7.8)0 |  |
| Triple negative | 30 (18.3) | 19 (16.8) | 11 (21.6) |  |
| Estrogenic receptor |  |  |  |  0.333 |
| Negative | 40 (24.0) | 25 (21.7) | 15 (28.8) | < |
| Positive | 127 (76.0)0 | 90 (78.3) | 37 (71.2) |  |
| Ki67 |  |  |  | <0.220 |
| 14%< | 68 (43.9) | 43 (40.2) | 25 (52.1) |  |
| >14% | 87 (56.1) | 64 (59.8) | 23 (47.9) |  |
| Neoadjuvant chemotherapy |  |  |  | <0.715 |
| No | 117 (70.1)0 | 82 (71.3) | 35 (67.3) |  |
| Yes | 50 (29.9) | 33 (28.7) | 17 (32.7) |  |
| Note: Data were presented as No. (%) or mean ± SD.  |